Moxetumomab pasudotox and Recombinate recombinant
Determining the interaction of Moxetumomab pasudotox and Recombinate recombinant and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: moxetumomab pasudotox
Brand name: Lumoxiti
Synonyms: Moxetumomab Pasudotox
Generic Name: antihemophilic factor
Brand name: Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Hemofil-M, Koate-DVI, Monoclate-P, Jivi, Obizur
Synonyms: Recombinate (recombinant), Recombinate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Moxetumomab pasudotox-Recombivax
- Moxetumomab pasudotox-Recombivax HB
- Moxetumomab pasudotox-Recombivax HB Adult
- Moxetumomab pasudotox-Recombivax HB Dialysis Formulation
- Moxetumomab pasudotox-Recombivax HB Pediatric/Adolescent
- Moxetumomab pasudotox-Recort Plus
- Recombinate recombinant-Moxetumomab Pasudotox-tdfk
- Recombinate recombinant-Moxetumomab pasudotox-tdfk Intravenous
- Recombinate recombinant-Moxifloxacin
- Recombinate recombinant-Moxifloxacin (Systemic)
- Recombinate recombinant-Moxifloxacin Hydrochloride
- Recombinate recombinant-Moxifloxacin Injection